

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

COR-L311

RRID:CVCL_2412

Type: Cell Line

Proper Citation

RRID:CVCL_2412

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2412

Proper Citation: RRID:CVCL_2412

Description: Cell line COR-L311 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:22460905](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COR-L311

Synonyms: CORL311

Cross References: CLO:CLO_0002591, CLDB:cl881, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN10987984, cancercellines:CVCL_2412, Cell_Model_Passport:SIDM00509, Cosmic:687980, Cosmic:1609513, Cosmic-CLP:687980, DepMap:ACH-000187, ECACC:96020721, EGA:EGAS00001000978, GDSC:687980, GEO:GSM886958, GEO:GSM888027, GEO:GSM1669700, IARC_TP53:30026, LiGeA:CCLE_088, Pharmacodb:CORL311_246_2019, PRIDE:PXD030304, Progenetix:CVCL_2412, Wikidata:Q54814285

ID: CVCL_2412

Record Creation Time: 20220427T215516+0000

Record Last Update: 20260815T232114+0000

Ratings and Alerts

No rating or validation information has been found for COR-L311.

No alerts have been found for COR-L311.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

He T, et al. (2024) Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies. Cancer cell, 42(8), 1336.

Duplaquet L, et al. (2024) Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. Cancer cell, 42(8), 1352.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports, 39(7), 110814.